Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Traws Pharma's Debt-to-Equity or its related term are showing as below:
TRAW's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Traws Pharma Debt-to-Equity Related Terms
Traws Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Traws Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRAW vs CNSP, MTVA, LIMN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Traws Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (TRAW) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Traws Pharma and its competitors. According to the industry distribution chart, Traws Pharma ranks #999999 out of 971 companies in the Biotechnology industry.
Is Traws Pharma's Debt-to-Equity too high?
Traws Pharma's current Debt-to-Equity is 0.00. Based on the distribution chart, Traws Pharma ranks #999999 out of 971 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Traws Pharma has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Debt-to-Equity compare to CNSP and MTVA?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #999999 out of 971 companies for Debt-to-Equity. This places Traws Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Traws Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traws Pharma's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $13.03, compared to a current price of $0.53 — trading 95.9% below its estimated fair value. The current Debt-to-Equity is 0.00. Traws Pharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Traws Pharma (TRAW), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traws Pharma (TRAW) Overvalued in 2026?
Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued.
The current stock price of $0.53 is trading 95.9% below its estimated GF Value™ of $13.03.
GuruFocus considers Traws Pharma to be Possible Value Trap.
Key valuation signals for TRAW:
Debt-to-Equity: 0.00
GF Value™: $13.03 vs. price of $0.53 (95.9% below fair value)
No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
40GF Score
Get the complete analysis for TRAW
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRAW has been successfully added to your 
